Aquaporin-4 autoantibodies in a paraneoplastic context

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Background: The neuromyelitis optica IgG autoantibody (NMO-IgG) is a validated biomarker for NMO and an emerging spectrum of inflammatory central nervous system-demyelinating disorders. Its antigen is the astrocytic water channel aquaporin-4; NMO-IgG has not been described in a cancer context. Objectives: To report (1) neurologic and oncologic correlates for patients incidentally identified as NMO-IgG seropositive in a blinded evaluation for paraneoplastic autoantibodies and (2) the frequency of cancer in NMO-IgG-seropositive patients. Design: Observational, retrospective case series. Setting: Neuroimmunology Laboratory and Neurology Clinical Practice, Mayo Clinic College of Medicine. Patients and Methods: From 1998 to 2007, we detected NMO-IgG in 2 patient groups: (1) 31 patients (88% female) identified incidentally among 180 000 patients evaluated for paraneoplastic autoantibodies and (2) 141 patients identified through physician-requested serological evaluation for a suspected NMO-spectrum disorder. Results: In the first group, clinical information was available for 28 patients (90%). An NMO-spectrum disorder was diagnosed in 26 patients (93%), of whom 6 had a neoplasm (5 carcinomas [2 breast, 1 lung, 1 thymic, and 1 uterine cervical] and 1 B-cell lymphoma) and 1 had monoclonal gammopathy. In 4 patients, NMO-related symptoms followed neoplasia detection (median, 14 [range 3-18] months), and in 2 patients, symptoms preceded neoplasia detection (by 5 and 3 months). Two patients had carcinoma (1 breast and 1 lung) without neurological evidence of an NMO-spectrum disorder. In the second group, neoplasms were recorded in 7 seropositive patients (5.0%) with a clinically diagnosed NMO-spectrum disorder: 3 carcinomas (all breast), 1 thyroid Hürthle cell, 1 carcinoid, 1 pituitary somatotropinoma, and 1 B-cell lymphoma. An eighth patient had monoclonal gammopathy. Conclusions: Aquaporin-4-specific IgG in some cases of NMO may reflect a paraneoplastic immune response. The clinical utility of this autoantibody as a cancer marker warrants prospective investigation.

Original languageEnglish (US)
Pages (from-to)629-632
Number of pages4
JournalArchives of Neurology
Volume65
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Aquaporin 4
Autoantibodies
Neuromyelitis Optica
Immunoglobulin G
Neoplasms
Paraproteinemias
B-Cell Lymphoma
Breast Neoplasms
Lung
Aquaporins
Second Primary Neoplasms
Central Nervous System Diseases
Carcinoid Tumor
Demyelinating Diseases
Neurology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Aquaporin-4 autoantibodies in a paraneoplastic context. / Pittock, Sean J; Lennon, Vanda A.

In: Archives of Neurology, Vol. 65, No. 5, 05.2008, p. 629-632.

Research output: Contribution to journalArticle

@article{f0a19e2d95f4485283e8f23a04f7ab07,
title = "Aquaporin-4 autoantibodies in a paraneoplastic context",
abstract = "Background: The neuromyelitis optica IgG autoantibody (NMO-IgG) is a validated biomarker for NMO and an emerging spectrum of inflammatory central nervous system-demyelinating disorders. Its antigen is the astrocytic water channel aquaporin-4; NMO-IgG has not been described in a cancer context. Objectives: To report (1) neurologic and oncologic correlates for patients incidentally identified as NMO-IgG seropositive in a blinded evaluation for paraneoplastic autoantibodies and (2) the frequency of cancer in NMO-IgG-seropositive patients. Design: Observational, retrospective case series. Setting: Neuroimmunology Laboratory and Neurology Clinical Practice, Mayo Clinic College of Medicine. Patients and Methods: From 1998 to 2007, we detected NMO-IgG in 2 patient groups: (1) 31 patients (88{\%} female) identified incidentally among 180 000 patients evaluated for paraneoplastic autoantibodies and (2) 141 patients identified through physician-requested serological evaluation for a suspected NMO-spectrum disorder. Results: In the first group, clinical information was available for 28 patients (90{\%}). An NMO-spectrum disorder was diagnosed in 26 patients (93{\%}), of whom 6 had a neoplasm (5 carcinomas [2 breast, 1 lung, 1 thymic, and 1 uterine cervical] and 1 B-cell lymphoma) and 1 had monoclonal gammopathy. In 4 patients, NMO-related symptoms followed neoplasia detection (median, 14 [range 3-18] months), and in 2 patients, symptoms preceded neoplasia detection (by 5 and 3 months). Two patients had carcinoma (1 breast and 1 lung) without neurological evidence of an NMO-spectrum disorder. In the second group, neoplasms were recorded in 7 seropositive patients (5.0{\%}) with a clinically diagnosed NMO-spectrum disorder: 3 carcinomas (all breast), 1 thyroid H{\"u}rthle cell, 1 carcinoid, 1 pituitary somatotropinoma, and 1 B-cell lymphoma. An eighth patient had monoclonal gammopathy. Conclusions: Aquaporin-4-specific IgG in some cases of NMO may reflect a paraneoplastic immune response. The clinical utility of this autoantibody as a cancer marker warrants prospective investigation.",
author = "Pittock, {Sean J} and Lennon, {Vanda A}",
year = "2008",
month = "5",
doi = "10.1001/archneur.65.5.629",
language = "English (US)",
volume = "65",
pages = "629--632",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Aquaporin-4 autoantibodies in a paraneoplastic context

AU - Pittock, Sean J

AU - Lennon, Vanda A

PY - 2008/5

Y1 - 2008/5

N2 - Background: The neuromyelitis optica IgG autoantibody (NMO-IgG) is a validated biomarker for NMO and an emerging spectrum of inflammatory central nervous system-demyelinating disorders. Its antigen is the astrocytic water channel aquaporin-4; NMO-IgG has not been described in a cancer context. Objectives: To report (1) neurologic and oncologic correlates for patients incidentally identified as NMO-IgG seropositive in a blinded evaluation for paraneoplastic autoantibodies and (2) the frequency of cancer in NMO-IgG-seropositive patients. Design: Observational, retrospective case series. Setting: Neuroimmunology Laboratory and Neurology Clinical Practice, Mayo Clinic College of Medicine. Patients and Methods: From 1998 to 2007, we detected NMO-IgG in 2 patient groups: (1) 31 patients (88% female) identified incidentally among 180 000 patients evaluated for paraneoplastic autoantibodies and (2) 141 patients identified through physician-requested serological evaluation for a suspected NMO-spectrum disorder. Results: In the first group, clinical information was available for 28 patients (90%). An NMO-spectrum disorder was diagnosed in 26 patients (93%), of whom 6 had a neoplasm (5 carcinomas [2 breast, 1 lung, 1 thymic, and 1 uterine cervical] and 1 B-cell lymphoma) and 1 had monoclonal gammopathy. In 4 patients, NMO-related symptoms followed neoplasia detection (median, 14 [range 3-18] months), and in 2 patients, symptoms preceded neoplasia detection (by 5 and 3 months). Two patients had carcinoma (1 breast and 1 lung) without neurological evidence of an NMO-spectrum disorder. In the second group, neoplasms were recorded in 7 seropositive patients (5.0%) with a clinically diagnosed NMO-spectrum disorder: 3 carcinomas (all breast), 1 thyroid Hürthle cell, 1 carcinoid, 1 pituitary somatotropinoma, and 1 B-cell lymphoma. An eighth patient had monoclonal gammopathy. Conclusions: Aquaporin-4-specific IgG in some cases of NMO may reflect a paraneoplastic immune response. The clinical utility of this autoantibody as a cancer marker warrants prospective investigation.

AB - Background: The neuromyelitis optica IgG autoantibody (NMO-IgG) is a validated biomarker for NMO and an emerging spectrum of inflammatory central nervous system-demyelinating disorders. Its antigen is the astrocytic water channel aquaporin-4; NMO-IgG has not been described in a cancer context. Objectives: To report (1) neurologic and oncologic correlates for patients incidentally identified as NMO-IgG seropositive in a blinded evaluation for paraneoplastic autoantibodies and (2) the frequency of cancer in NMO-IgG-seropositive patients. Design: Observational, retrospective case series. Setting: Neuroimmunology Laboratory and Neurology Clinical Practice, Mayo Clinic College of Medicine. Patients and Methods: From 1998 to 2007, we detected NMO-IgG in 2 patient groups: (1) 31 patients (88% female) identified incidentally among 180 000 patients evaluated for paraneoplastic autoantibodies and (2) 141 patients identified through physician-requested serological evaluation for a suspected NMO-spectrum disorder. Results: In the first group, clinical information was available for 28 patients (90%). An NMO-spectrum disorder was diagnosed in 26 patients (93%), of whom 6 had a neoplasm (5 carcinomas [2 breast, 1 lung, 1 thymic, and 1 uterine cervical] and 1 B-cell lymphoma) and 1 had monoclonal gammopathy. In 4 patients, NMO-related symptoms followed neoplasia detection (median, 14 [range 3-18] months), and in 2 patients, symptoms preceded neoplasia detection (by 5 and 3 months). Two patients had carcinoma (1 breast and 1 lung) without neurological evidence of an NMO-spectrum disorder. In the second group, neoplasms were recorded in 7 seropositive patients (5.0%) with a clinically diagnosed NMO-spectrum disorder: 3 carcinomas (all breast), 1 thyroid Hürthle cell, 1 carcinoid, 1 pituitary somatotropinoma, and 1 B-cell lymphoma. An eighth patient had monoclonal gammopathy. Conclusions: Aquaporin-4-specific IgG in some cases of NMO may reflect a paraneoplastic immune response. The clinical utility of this autoantibody as a cancer marker warrants prospective investigation.

UR - http://www.scopus.com/inward/record.url?scp=43549120250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549120250&partnerID=8YFLogxK

U2 - 10.1001/archneur.65.5.629

DO - 10.1001/archneur.65.5.629

M3 - Article

C2 - 18474738

AN - SCOPUS:43549120250

VL - 65

SP - 629

EP - 632

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 5

ER -